Malondialdehyde-specific IGM antibodies define residual atherothrombotic risk

Background and Aims: Lipid peroxidation products like malondialdehyde(MDA) modify plaque components and are recognized by natural IgM antibodies. Titres of these inversely correlate with cardiovascular events, the mechanism of which is still poorly understood. Amongst others, MDA IgMs inhibit extracellular vesicle(EV)-induced clotting and thrombosis. Besides EVs, other plaque components are prothrombotic and MDA modified. We thus hypothesize that MDA IgMs are protective through inhibition of atherothrombosis.